Pricing Log in Create free account

Bicycle Therapeutics PLC Sponsored ADR (BCYC) vs Compugen Ltd. (CGEN)

Bicycle Therapeutics PLC Sponsored ADR and Compugen Ltd. are both Biotechnology companies. Bicycle Therapeutics PLC Sponsored ADR and Compugen Ltd. are of similar size ($187.6M and $182.9M). Bicycle Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Compugen Ltd. trades at 5.5×. Compugen Ltd. grew revenue faster over the last twelve months: 234.2% against 217.4%. Compugen Ltd. has the higher net margin (47.6% vs −311.1%) and the higher return on invested capital (0.00% vs −64,747.5%). Across the 18 metrics below, Compugen Ltd. leads on 13 and Bicycle Therapeutics PLC Sponsored ADR on 5.

Valuation

Metric BCYC CGEN Biotechnology median
P/E n/m 5.47 8.42
P/S 4.11 2.66 10.01
P/B 0.49 2.22 2.21
Price to free cash flow n/m 4.92 21.01
EV/EBITDA 1.16 2.36 0.61
EV/Sales (3.88) 0.97 9.41
Earnings yield (75.83%) 18.27% (31.85%)
Free cash flow yield (82.88%) 20.34% (24.58%)

Profitability

Metric BCYC CGEN Biotechnology median
Gross margin 100.00% 86.89% 65.16%
Operating margin (343.60%) 40.94% 0.00%
Net margin (311.11%) 47.55% 0.00%
Free cash flow margin (340.29%) 54.10% 0.00%
Return on equity (32.30%) 47.85% (56.36%)
Return on assets (26.47%) 23.86% (48.04%)
Return on invested capital (64,747.54%) 0.00% 0.00%

Growth

Metric BCYC CGEN Biotechnology median
Revenue growth (TTM) 217.44% 234.18% 6.02%
EPS growth (last fiscal year) (8.97%) 337.50% 30.26%
Revenue growth, 5-year CAGR 47.52% 105.20% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCYC CGEN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.08 5.72 4.72
Net debt to EBITDA 2.61 (4.65) 0.96

Dividend

Metric BCYC CGEN Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric BCYC CGEN Biotechnology median
Market cap 182.88m 187.56m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack